Back to discover
Drug

Apixaban

Established medicine
ClassCoagulation factor X inhibitorResearchOngoing clinical research

Also known as Eliquis, apixabán, apixabanum.

RxNorm1364430ChEMBLCHEMBL231779ATCB01AF02UNII3Z9Y7UWC1J
4
Research papers
43
Active clinical trials
Coagulation factor X
Primary target
2
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase 3, Multicenter, Randomized, Open-Label, Study to Evaluate REGN7508, A Factor XI Monoclonal Antibody, Versus Apixaban and Enoxaparin for Prophylaxis of Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-APEX)

Clinical trial2026-10-08Results expected Q1 2027 · ClinicalTrials.gov

COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation

Clinical trial2026-10-01Results expected Q4 2027 · ClinicalTrials.gov

Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia

Clinical trial2026-09-24Results expected Q1 2030 · ClinicalTrials.gov

CSP #2037T - Veterans Affairs Learning Health System Initiative to Assess Novel Screening vs. Usual Care and Treatment With Apixaban vs. Rivaroxaban in Veterans With Atrial Fibrillation (VALIANT-AF-T) Trial

Clinical trial2026-09-23Results expected Q4 2032 · ClinicalTrials.gov

Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury

Clinical trial2026-09-09Results expected Q3 2027 · ClinicalTrials.gov

The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis

Clinical trial2026-08-31Primary completion · ClinicalTrials.gov

Generic medicine authorisation: Apixaban Accord (EMA)

Regulatory2020-07-23EMA

Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.

Research2020-03-29The New England journal of medicine

Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis.

Research2015-12-22Journal of clinical pharmacology

Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects.

Research2015-07-15Clinical therapeutics

Marketing authorisation: Eliquis (EMA)

Regulatory2011-05-18EMA

Apixaban in patients with atrial fibrillation.

Research2011-02-10The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Apixaban
Aliases & brands
Eliquisapixabánapixabanum
RxNorm CUI
1364430
ChEMBL ID
CHEMBL231779
ATC codes
B01AF02
UNII
3Z9Y7UWC1J
Primary mechanism
Coagulation factor X inhibitor
Regulatory jurisdictions
ema

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Coagulation factor X
F10 · P00742
INHIBITORCoagulation factor X inhibitor

Regulatory timeline

2 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2011-05-18
Latest approval
2020-07-23
Authorities
EMA
Total events
2
emaEuropean Medicines Agency· 2 events
2020-07-23Generic approvalMarket
Generic medicine authorisation: Apixaban Accord (EMA)
Indication: Adults Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or… Show full indication

Adults Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).   Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).   Paediatric population  Treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age. Adults  Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.   Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).   Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).   Paediatric population Treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age.

Evidence ↗
2011-05-18Original application approval
Marketing authorisation: Eliquis (EMA)
Indication: Treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age. AdultsPrevention of venous… Show full indication

Treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age. AdultsPrevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).Paediatric population Treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age. AdultsPrevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age. 

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

185 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
185
registered trials across all phases
LATEST COMPLETION 2026
43
Active studies
37
Recruiting
119
Late-stage (III+)
98
Completed
44
Discontinued
PHASE DISTRIBUTIONn = 185
Early Phase 11Phase 128Phase 1 / 22Phase 235Phase 2 / 34Phase 357Phase 446Phase N / A12

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

CSP #2037T - Veterans Affairs Learning Health System Initiative to Assess Novel Screening vs. Usual Care and Treatment With Apixaban vs. Rivaroxaban in Veterans With Atrial Fibrillation (VALIANT-AF-T) Trial

RecruitingPH IVKey trialVA Office of Research and Developmentn=10,0002033

Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia

RecruitingPH IVMcGill University Health Centre/Research Institute of the McGill University Health Centren=3002030

Secondary Prevention of Venous Thromboembolism in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis (STREAM-Line Study)

RecruitingPH IVOttawa Hospital Research Instituten=3302029

A Multicenter Prospective Randomized Study to Evaluate the Efficacy of Apixaban and Clopidogrel on the Prevention of Recurrent Ischemic Stroke in Patients With Atrial Fibrillation and Cerebral Atherosclerosis

Not yet recruitingPH IVYonsei Universityn=5862029

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Patients With Venous Thromboembolism.

Active, not recruitingPH IVKey trialHerlev and Gentofte Hospitaln=5,0002029

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase I, Randomized, Single-blind, Placebo-controlled Study to Further Characterize Andexanet Posology and Assess the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants

CompletedPH IAstraZenecan=1912026

AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation

CompletedPH IIIOslo University Hospitaln=3602026

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism

CompletedPH IVKey trialOttawa Hospital Research Instituten=2,7602025

A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy

CompletedPH IIIAcademic and Community Cancer Research Unitedn=3702025

Randomized Controlled Trial of Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism

CompletedPH IVBrigham and Women's Hospitaln=6002025

A Pivotal, Randomized, Single-dose, Open-label, Four-Way Crossover, BE Study of TAH3311 (Apixaban ODF) Under Fasted and Fed Conditions vs. ELIQUIS® Oral Tablet Under Fasted Condition in Healthy Volunteers

CompletedPH IITAHO Pharmaceuticals Ltd.n=602025

Research activity

4 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
2011–2020
Major research themes5
Factor Xa Inhibitors2Kidney Failure, Chronic1Pyrazoles1Pyridones1Renal Dialysis1
Journals, researchers & institutions
Top journals
  • The New England journal of medicine2
  • Clinical therapeutics1
  • Journal of clinical pharmacology1
Leading researchers
  • Frost C2
  • Song Y2
  • Wang J2
  • Wang X2
  • Afzal R1
  • Agnelli G1
  • Avezum A1
  • Badawy S1
Leading institutions
free-text, unnormalised
  • Orlando Clinical Research Center1
  • Population Health Research Institute1
  • University of Perugia1

Related diseases

1 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas
Hemorrhage2

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Dalteparin

Studied across 5 of the same disease areas as Apixaban in the shared literature.

5 shared diseases1 shared paper
Aspirin

Studied across 4 of the same disease areas as Apixaban in the shared literature.

4 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.